Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GOSS with free AI briefings, catalyst countdowns, and dilution alerts.

GOSS · Gossamer Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$51.2M Cash on Hand
4.5mo Cash Runway
22.2% Short Interest
$83.4 Analyst Target (6)
Follow GOSS by email Get an email when GOSS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GOSS, unsubscribe in one click. Privacy

📣 What GOSS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Seralutinib Pulmonary Arterial Hypertension Phase 3 · NCT06274801 Recruiting
GB001 Asthma Phase 2 · NCT03683576 Completed
GB002 Pulmonary Arterial Hypertension Phase 2 · NCT04816604 Terminated
GB004 Ulcerative Colitis Phase 1 · NCT03860896 Completed
CD11b Agonist GB1275 Pancreatic Adenocarcinoma Phase 1 · NCT04060342 Terminated
GB5121 CNS Lymphoma Phase 1 · NCT05242146 Terminated
Nab-paclitaxel Pancreatic Adenocarcinoma Phase 1 · NCT04060342 Terminated

Also used in these trials (approved or third-party drugs, not GOSS's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GOSS holds $51.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $34.5M/quarter from operations, an estimated runway of 4.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GOSS files for a raise →

👥 Who Owns GOSS

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
683 Capital Management, LLC Institution (13G, 5%+) 49,868,571 815.33% 2026-06-04
Context Capital Management, LLC Institution (13G, 5%+) 48,835,788 798.44% 2026-06-04
D. E. Shaw & Co., L.P. Institution (13G, 5%+) 34,609,565 565.85% 2026-07-22
Faheem Hasnain
President & CEO, Director · +12.92M options
Insider 6,245,866 102.12% 2026-01-02
Waage Christian
EVP, Tech Ops and Admin · +4.97M options
Insider 882,175 14.42% 2026-01-02
Bryan Giraudo
COO/CFO · +8.12M options
Insider 869,747 14.22% 2026-01-02
FMR LLC Institution (13G, 5%+) 667,465 10.91% 2026-10-30
Richard Aranda
Chief Medical Officer · +2.35M options
Insider 465,645 7.61% 2026-01-02
Opaleye Management Inc. Institution (13G, 5%+) 426,989 6.98% 2026-09-30
Robert Paul JR Smith
Chief Commercial Officer · +6.93M options
Insider 285,898 4.67% 2026-01-02
Caryn Peterson
Chief Development Officer · +7.63M options
Insider 259,333 4.24% 2026-01-02
Worth Venture Partners, Llc Institution (13F) 204,988 3.35% 2026-09-30

Share count 6,116,390 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-23
filed 2026-09-25
Ciongoli Gregory Austin
Option award (A) 30,000 – –
2026-09-23
filed 2026-09-25
Drynan Skye
Option award (A) 10,000 – –
2026-09-23
filed 2026-09-25
Nathan Steven D
Option award (A) 10,000 – –
2026-09-23
filed 2026-09-25
Quisel John D
Option award (A) 10,000 – –
2026-09-23
filed 2026-09-25
Daniel Thomas O
Option award (A) 10,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full GOSS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GOSS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.